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Abstract The peptide hormone ghrelin is a potent orexigen
produced predominantly in the stomach. It has a number of
other biological actions, including roles in appetite stimu-
lation, energy balance, the stimulation of growth hormone
release and the regulation of cell proliferation. Recently,
several ghrelin gene splice variants have been described.
Here, we attempted to identify conserved alternative splicing
of the ghrelin gene by cross-species sequence comparisons.
We identified a novel human exon 2-deleted variant and
provide preliminary evidence that this splice variant and in1-
ghrelin encode a C-terminally truncated form of the ghrelin
peptide, termed minighrelin. These variants are expressed in
humans and mice, demonstrating conservation of alternative
splicing spanning 90 million years. Minighrelin appears to
have similar actions to full-length ghrelin, as treatment with
exogenous minighrelin peptide stimulates appetite and
feeding in mice. Forced expression of the exon 2-deleted
preproghrelin variant mirrors the effect of the canonical
preproghrelin, stimulating cell proliferation andmigration in
the PC3 prostate cancer cell line. This is the first study to
characterise an exon 2-deleted preproghrelin variant and to
demonstrate sequence conservation of ghrelin gene-derived
splice variants that encode a truncated ghrelin peptide. This
adds further impetus for studies into the alternative splicing
of the ghrelin gene and the function of novel ghrelin peptides
in vertebrates.
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Introduction
Ghrelin is a 28-amino acid peptide hormone produced in the
stomach and has potent appetite-stimulating effects [1, 2].
Ghrelin was initially described as a growth hormone-re-
leasing peptide and is now recognised to have a diverse range
of functions in a number of cell types and systems, including
roles in energy balance, appetite regulation and food-seeking
behaviour, insulin regulation and cell proliferation [1–4].
The ghrelin gene (GHRL) and the coding exons of the
derived preprohormone, preproghrelin, are conserved in a
wide range of species including fish [5], turtles [6], birds [7]
and mammals [8]. In humans, exons 1 to 4 encode the
117-amino acid preproghrelin, with exons 1 and 2 coding for
the 28-amino acid peptide hormone ghrelin [1]. After
cleavage of a 23-amino acid signal peptide, proghrelin is
processed to form ghrelin, and the third ghrelin residue
(serine) is post-translationally octanoylated (acylated) by the
enzyme ghrelin O-acyl transferase (GOAT, encoded by
MBOAT4) [9, 10]. TheC-terminus of proghrelin (encoded by
exons 3 and 4) is further processed to give rise to the
23-amino acid peptide hormone obestatin [11], which has
independent actions from ghrelin [12].
We and others have previously demonstrated that the
ghrelin gene locus is complex and gives rise to numerous
transcripts that could encode a wide range of peptides [13,
14]. A number of ghrelin variants have been characterised
in humans [13] and transcripts containing intronic
sequence, in1-ghrelin and in2c-ghrelin, have recently been
described [15, 16]. Intron 2 cryptic (in2c) ghrelin is an
insulin-regulated transcript that contains intron 2-derived
exons and the coding region for ghrelin, but lacks the
obestatin sequence [16]. The in1-ghrelin transcript contains
exon 1, intron 1 and exon 2, and the inclusion of intron 1
leads to a truncation of the ghrelin peptide sequence [15].
We recently reported an exon 2-deleted splice variant in
mouse and sheep [17]. In this study, we sought to deter-
mine whether any ghrelin gene-derived splice variants are
conserved across vertebrates and present preliminary
findings on the function of splice variants encoding derived
short, C-terminally truncated ghrelin peptides (here termed
minighrelin).
Materials and methods
Bioinformatics
Ghrelin gene (GHRL) sequences (from genomes and tran-
scriptomes) were derived from the UCSC multiway tool,
NCBI GenBank [18], and from the NCBI Short Read
Archive (SRA) [19]. Putative GHRL sequences were inter-
rogated using BLAST [20] in a local instance of the Ruby-
based SequenceServer (http://www.sequenceserver.com),
gmap v2013-06-27 (a genomic mapping and alignment
program formRNAand EST sequences) with the parameters
–cross-species –align –direction=sense_force -Y [21], and
custom Perl scripts with BioPerl modules [22]. MUSCLE
[23] was used for protein sequence alignments of ghrelin
gene orthologs, using the human sequence as the reference.
Cell culture
Cell lines were originally obtained from the American
Type Culture Collection (ATCC, Rockville, MD, USA).
The PC3 (ATCC CRL-1435), DU145 (ATCC HTB-81),
LNCaP (ATCC CRL-1740) and 22Rv1 (ATCC CRL-2505)
prostate cancer cell lines were maintained in Roswell Park
Memorial Institute (RPMI) 1640 medium (Invitrogen,
Mulgrave, VIC, Australia) with 10 % New Zealand Cos-
mic Calf Serum (FCS, Thermo Fisher Scientific Australia,
Scoresby, VIC, Australia) supplemented with 100 U/mL
penicillin G and 100 lg/mL streptomycin (Invitrogen). The
non-tumourigenic RWPE-1 (ATCC CRL-11609) and the
transformed, tumourigenic RWPE-2 (ATCC CRL-11610)
prostate epithelium-derived cell lines were cultured in
keratinocyte serum-free medium (KSFM) (Invitrogen)
supplemented with 50 lg/mL bovine pituitary extract and
5 ng/mL epidermal growth factor (Invitrogen). All cell
lines were passaged at 2- to 3-day intervals at 70 % con-
fluency using TrypLE Select (Invitrogen). Cell morphology
and viability were monitored by microscopic observation
and regular PCR testing was performed (Universal Myco-
plasma Detection Kit, ATCC) to ensure that cells were not
contaminated with Mycoplasma.
Identification of human exon 2-deleted
preproghrelin
Human exon-2 deleted preproghrelin was cloned as fol-
lows: total RNA was harvested from cultured cells using an
RNeasy Plus Mini Kit (QIAGEN, Germantown, MD, USA)
according to the manufacturer’s instructions. Next, 2 lg
total RNA was subjected to DNase I digestion (amplifica-
tion grade, Invitrogen), immediately followed by cDNA
synthesis with SuperScript III using oligo(dT)18 primers
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(Invitrogen) according to the manufacturer’s instructions.
RT-PCR primers spanning exon 1 and 3 of preproghrelin
(50-CATGCTCTGGCTGGACTTGG-30 and 50-GACAG
CTTGATTCCAACATCAAAGG-30) were designed using
PerlPrimer [24]. RT-PCR using tissue (normal human tis-
sue cDNA panel HMRT102 purchased from OriGene,
Rockville, MD, USA) and cultured cells was performed in
a total reaction volume of 30 lL containing 19 PCR
buffer, 0.2 mM deoxynucleotide triphosphates, 1.5 mM
MgCl2, 0.2 lM primers, 1 lL cDNA and 1 unit of Plat-
inum Taq DNA Polymerase (Invitrogen) on a PTC-200
thermal cycler (MJ Research, Watertown, MA, USA)
according to the manufacturer’s instructions, with an
annealing temperature of 61 C. Negative (no-template)
controls were performed. RT-PCR products were purified
using a MinElute (QIAGEN) PCR Purification Kit, cloned
into pCR4-TOPO (Invitrogen), transformed into One Shot
MAX Efficiency DH5a-T1R chemically competent cells
(Invitrogen) and sequenced at the Australian Genome
Research Facility (AGRF, Brisbane, Australia) using Big-
Dye III (Applied Biosystems, Foster City, CA, USA).
Food intake as a measure of in vivo function
of ghrelin peptides
Acylated (octanoylated) and desacyl 28-AA ghrelin pep-
tides (H-GSSFLSPEHQRVQQRKESKKPPAKLQPR-OH)
and 13-AA minighrelin peptides (H-GSSFLSPEHQRVQ-
OH) were commercially synthesised (Mimotopes, Mel-
bourne, VIC, Australia). Male 16-week-old C57BL/6J
mice, purchased from the Animal Resources Centre (Perth,
Western Australia), were housed separately and handled
daily for 1 week with unrestricted access to standard chow
and drinking water to acclimatise them to experimental
conditions. Mice were then injected intraperitoneally with
2 nmol/mouse acyl ghrelin, desacyl ghrelin, acyl
minighrelin, desacyl minighrelin, or saline (vehicle) (n = 6
per group except for the minighrelin treatment, where
n = 5). This dose of acyl ghrelin (2 nmol/mouse) has
previously been demonstrated to stimulate appetite in mice
[25, 26]. Mice were injected at 09:00 (light phase) and
given pre-weighed chow pellets. At 4 h post injection, the
remaining chow pellets were weighed and the cumulative
food intake per mouse was determined to the nearest 0.1 g
(pre-injection pellet weight minus post-injection pellet
weight). Experiments were carried out with approval of the
Animal Ethics Committee, University of Queensland.
Forced overexpression of human exon 2-deleted
preproghrelin
Coding regions of human exon 2-deleted preproghrelin and
canonical preproghrelin were commercially synthesised
and cloned into OriGene pCMV6-AC plasmid vectors (Blue
Heron Biotechnology, Bothell, WA, USA). Constructs, and
empty vector controls, were transformed into E. coli DH5a
cells (Invitrogen) and purified using a QIAGEN plasmid
purification kit, according to the manufacturer’s instruc-
tions. To produce a control cell line expressing the vector
only, the PC3 prostate cancer cell line was transfected with
pCMV6-AC plasmid DNA using Lipofectamine 2000
reagent (Invitrogen), according to the manufacturer’s
instructions. Stably overexpressing PC3 prostate cancer
cells were selected with 600 lg/mL G418 antibiotic (In-
vitrogen). Overexpression of ghrelin variants was con-
firmed by semi-quantitative RT-PCR (as described above).
Cell proliferation assays
Cell proliferation assays were performed using the
xCELLigence Real-Time Cell Analyzer (RTCA) system
(ACEA Biosciences, San Diego, CA, USA), using E plates,
according to the manufacturer’s instructions. Briefly, cell
lines overexpressing exon 2-deleted preproghrelin, canon-
ical preproghrelin, or empty vector were cultured until they
were 70 % confluent, detached from the cell culture flask
using trypsin/EDTA (Invitrogen) and collected by cen-
trifugation. Cells were then added to E plates at a density of
5000 cells/well in growth medium with 10 % New Zealand
Cosmic Calf serum (FCS) (Thermo Fisher Scientific).
Proliferation was measured for up to 72 h and compared to
the rate of proliferation of cells expressing an empty vec-
tor. Each treatment (exon 2-deleted preproghrelin, canon-
ical preproghrelin and empty vector overexpressing cells)
was performed with three replicates, and the experiment
was performed independently three times.
Cell migration assay
Cell migration assays were performed using the xCELLi-
gence RTCA system and cell/invasion migration (CIM)
plates with 8 lm pores (ACEA Biosciences). The lower
well contained media with 10 % foetal calf serum as a
chemoattractant, and the cells were added to the upper well
at a density of 50,000 cells/insert in serum-free media.
Migration was observed in real time for up to 48 h. Each
‘treatment’ (exon 2-deleted preproghrelin, canonical pre-
proghrelin and empty vector overexpressing cells) was
performed with three replicates, and the experiment was
performed independently three times.
Statistical analyses
Statistical analyses were undertaken using GraphPad Prism
v5.04 (La Jolla, CA, USA) and R statistical software v3.0.2
(http://www.r-project.org). If a data set did not differ
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significantly from a normal distribution (P B 0.05, Shapiro–
Wilk test), the data were considered to have a ‘normal’ dis-
tribution and a parametric one-way ANOVA with Tukey’s
post hoc test was used to compare groups. If a data set dif-
fered significantly from a normal distribution (P C 0.05,
Shapiro–Wilk test), the Mann–Whitney U test (a general
non-parametric test for two groups) was utilised to test for a
difference between a treatment group and the control.
Results and discussion
Evidence of conserved exon skipping of the ghrelin
gene
We interrogated the ghrelin gene (GHRL) in 77 species,
representing all major vertebrate groups sequenced to date.
This analysis revealed that loss of exon 2 could be tolerated
in all taxa. Exon 2 ranges in size from 78 bp in the black
seabream teleost fish (Acanthopagrus schlegeli) [27] to
117 bp in humans (Online Resource 1). As the length of
exon 2 is divisible by three in all species, it is a symmet-
rical exon. Frequently, skipping of symmetrical exons does
not alter the reading frame of the encoded protein [28].
Indeed, the removal of exon 2 from putative preproghrelin
mRNAs of all species examined allows the retention of the
cognate preproghrelin reading frame. We recently descri-
bed an exon 2-deleted ghrelin splice variant in mice and
sheep [17]. The canonical human preproghrelin coding
sequence consists of 117 amino acids (AAs). The 28-AA
ghrelin peptide is encoded by exons 1 and 2, while exons 3
and 4 encode the 66-amino acid C-terminal peptide,
C-ghrelin, which contains the 23-amino acid peptide
obestatin encoded entirely by exon 3 [1, 11]. In contrast,
skipping of exon 2 would result in the translation of a
78-AA preprohormone, exon 2-deleted preproghrelin, and
would consist of a 13-AA C-terminally truncated ghrelin
peptide (hereafter termed minighrelin) that is directly fol-
lowed by the coding sequence of obestatin (Fig. 1a; Online
Resource 2).
In addition to evidence of conserved exon 2 ‘deletion’
(exon skipping), we noted that in1-ghrelin, a splice variant
previously cloned from the mouse [29], human and baboon
[15], also harbours a minighrelin peptide sequence. In1-
ghrelin contains exon 1, the short intron 1 and exon 2 [15].
In contrast to all other described variants (e.g. canonical
preproghrelin, in2c-ghrelin, exon 2-deleted preproghrelin
and exon 3-deleted preproghrelin), in1-ghrelin lacks exons
3 and 4. In accordance with genome-wide transcriptome
analyses [30], we speculate that inclusion of intronic (in-
tron 1 in its entirety) sequence promotes an alternative
polyadenylation site within exon 2 or the large intron 2
(*3 kb in human). Due to divergence in the C-terminal
region, in1-ghrelin differs greatly in size between species,
ranging from 45 AAs in black seabream, 46 AAs in sheep,
55 AAs in mouse, 117 AAs in human, to 124 AAs in the
naked mole rat (Fig. 1b). The common feature of in1-
ghrelin in all vertebrate species examined is the presence of
C-terminally truncated ghrelin sequence, minighrelin.
We recently described the insulin-responsive in2c-
ghrelin splice variant in prostate cancer cell lines, [16] and
while screening these cells, we identified a novel RT-PCR
amplicon (Fig. 2a). This amplicon was cloned from the
PC3 prostate cancer cell line (GenBank accession no.
KF921297), and from brain and uterus (Online Resource
3). Sanger sequencing revealed that it corresponds to the
predicted exon 2-deleted preproghrelin splice variant
(Figs. 2b, c). Orthologous full-length exon 2-preproghrelin
transcripts were identified in the mouse (GenBank acces-
sion no. AB111891) and sheep (GenBank accession no.
KF219676) [17]. In1-ghrelin and exon 2-deleted pre-
proghrelin transcripts are present in humans and mice,
which represents conservation spanning at least 90 million
years. We have cloned exon 2-deleted ghrelin gene-derived
transcripts from human, mouse and sheep, and the open
reading frame is conserved in multiple species, spanning
*400 million years of vertebrate evolution [31]. This is
consistent with, at the very least, mammalian-specific
alternative splicing of the ghrelin gene and is suggestive
of biologically functional ghrelin gene-derived splice
variants with C-terminally truncated ghrelin sequence
(minighrelin).
Minighrelin mimics canonical ghrelin function
The splice variants described here harbour C-terminally
truncated ghrelin peptide sequences that retain the first 13
amino acids of the peptide hormone, ghrelin, followed by
obestatin sequence. We investigated whether the truncated
ghrelin peptide derived from the exon 2-deleted splice
variant could mimic the functional effects of canonical
ghrelin. This region of the exon 2-deleted prepropeptide
retains the active core (the first five amino acids) of ghrelin,
which is required for the activation of its cognate receptor,
GHSR1a [32, 33], and for octanoylation of the peptide by
GOAT [34].
We first employed the classical assay for ghrelin func-
tion, food intake [3], to determine the effect of the
minighrelin peptide sequence on acute appetite stimulation.
Synthetic acylated 13-AA ghrelin (minighrelin) peptide
stimulated 4-h food intake during the light phase in non-
fasted C57BL/6J mice (Fig. 3a) (P B 0.05, Mann–Whitney
U test). Desacyl minighrelin did not stimulate food intake
(data not shown).
We next investigated the function of exon 2-deleted
preproghrelin in our model assay system, cultured prostate
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cancer cell lines [16, 35–37]. We employed the PC3
prostate cancer cell line, which expresses exon 2-deleted
preproghrelin (Fig. 2a), the processing enzymes necessary
to produce mature, acylated ghrelin, the octanoylating
enzyme GOAT [36] and the cognate ghrelin receptor,
GHSR1a [35]. A similar approach has been used to
demonstrate that the in1-ghrelin variant increases prolif-
eration in the MDA-MB-231 breast cancer cell line [15],
Fig. 1 Overview of exon 2-deleted preproghrelin and in1-ghrelin
open reading frames in vertebrates. Bioinformatic prediction of
a exon 2-deleted preproghrelin and b in1-ghrelin peptide sequences.
Nucleotide databases of diverse species were interrogated for the
preproghrelin gene (GHRL) sequences. Canonical coding sequences
(mRNA) are shown as green boxes, while the corresponding regions
of the signal peptide (purple), minighrelin (blue) and obestatin
(orange) are represented as boxes below
Fig. 2 Identification of human exon 2-deleted preproghrelin. a Rep-
resentative RT-PCR products from human normal prostate-derived
(RWPE-1, RWPE-2) and prostate cancer-derived (LNCaP, 22Rv1,
DU145, PC3) cell lines. Amplicons corresponding to in2c-ghrelin
variants (GenBank accession no. EF139854-55), canonical pre-
proghrelin coding exons and the novel exon 2-deleted preproghrelin
variant (GenBank accession no. KF921297) are indicated. M denotes
low-mass DNA molecular weight marker VIII (Roche). b Schematic
of canonical and exon 2-deleted preproghrelin sequences. Exons and
introns are shown as boxes and lines, respectively. c Schematic
protein structure of wild-type 117 preproghrelin encoded by exons 1,
2, 3 and 4. The sequence outlined in red indicates preproghrelin
peptide sequence that is absent in the exon 2-deleted preproghrelin
variant. Sequences of the signal peptide (purple), minighrelin (blue)
and obestatin (orange) are shown
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mirroring the effect of synthetic 28-AA ghrelin peptide
treatment [38]. Overexpression of exon 2-deleted pre-
proghrelin (which harbours a 13-AA ghrelin sequence) and
full-length preproghrelin (28-AA ghrelin sequence) sig-
nificantly increased cell proliferation and migration in the
PC3 prostate cancer cell line (Fig. 3b, c) (P B 0.05,
ANOVA with Tukey’s post hoc test). These findings are
consistent with our previous studies, which have demon-
strated that treatment of prostate cancer cell lines with
exogenous 28-AA ghrelin peptide stimulates cell prolifer-
ation [35, 37]. Ghrelin stimulates cell migration in cultured
cell lines derived from cancers of the brain [39], colon [40]
and pancreas [41]. For the first time, we show that
canonical preproghrelin and exon 2-deleted preproghrelin
also induce cell migration in a prostate cancer cell line.
These findings are in agreement with a very recent study
showing that a 19-AA putative human in1-ghrelin-derived
ghrelin peptide, which harbours the first 13 AAs of ghrelin,
acts via the cognate ghrelin receptor, GHSR1a, and is able
to mimic the effects of ghrelin [42]. Taken together, these
data suggest that naturally occurring ghrelin gene-derived
variants coding for a C-terminally truncated ghrelin peptide
sequence, minighrelin, are able to mimic the effect of
ghrelin.
Implications of this study
Aided by comparative genomics analysis, we present pre-
liminary evidence of the first conserved ghrelin gene-
derived splice variants since the discovery of ghrelin in
1999 [1]. Alternative splicing is a complex event where
protein diversity is increased from a relatively small
number of genes [43]. Molecular innovation of the ghrelin
gene, through alternative splicing, has largely been
reported in the literature as species specific. This includes
the recently described in2c-ghrelin in humans [16], the
mouse-specific ghrelin gene-derived transcript (GGDT)
with a novel first exon in intron 2 followed by exon 3 and 4
[44], and a variant with a 50 truncated exon 3 lacking the
N-terminus of obestatin in the red-eared slider turtle [6,
45]. An exon 3-deleted preproghrelin variant with a novel
C-terminal region is present in mouse [46] and human [37],
but absent in other mammals such as ruminants, where
skipping of exon 3 alone would result in a prematurely
truncated preproghrelin peptide (unpublished data). It has
been proposed that highly conserved alternative splicing
corresponds to molecular changes that are tolerated during
evolution [47, 48]. Here, we show that skipping exon 2 of
the ghrelin gene results in an open reading frame that is
highly conserved in vertebrates. While exon 2-deleted
preproghrelin produces a C-terminally truncated ghrelin
peptide, minighrelin, it is otherwise identical to canonical
preproghrelin. We also show that although vertebrate in1-
ghrelin sequences have a highly divergent C-terminus, they
all harbour an in-frame minighrelin peptide sequence.
The proteolytic cleavage of ghrelin gene-derived pep-
tides remains largely unresolved; however, there are some
commonly recognised preprohormone cleavage sites [49].
The obestatin peptide is spanned by an Arg (R) or Gln
(Q) in primates [11], and 10 years after its discovery the
proteases responsible for its cleavage have not been firmly
established. Similarly, minighrelin is spanned by Gln
(Q) in all but two species (the common shrew and anole
lizard, a discrepancy which may result from genome
sequencing errors) and by mono- or dibasic (Arginine and
Lysine) amino acid residues in all species except turtles
(Online Resource 2). The small size of the putative
minighrelin peptide (\1.5 kDa), and difficulty in
Fig. 3 Minighrelin mimics the function of ghrelin. a Effects of
intraperitoneal (i.p.) administration of synthetic human 28-AA acyl
ghrelin or 13-AA acyl minighrelin on short-term food intake in mice.
Four-month-old male C57BL/6 mice were injected i.p. with 2 nmol
acyl ghrelin (n = 6), 2 nmol acyl minighrelin (n = 5) or 100 ll
vehicle control (sterile saline; n = 6). Food intake (standard chow)
was measured 4 h after the administration of ghrelin peptides or
vehicle. Data points correspond to the mean 4-h food intake (±SEM).
*P B 0.05, relative to control (saline). Desacyl ghrelin and desacyl
minighrelin had no effect on food intake (data not shown). b Effect of
exon 2-deleted preproghrelin and canonical preproghrelin
overexpression on proliferation of PC3 prostate cancer cells after
60 h (compared to cells expressing vector alone). Data represent the
mean ± SEM of three experiments (n = 16 per treatment).
*P B 0.05, relative to control (empty vector). c Effect of exon
2-deleted preproghrelin and canonical preproghrelin overexpression
on cell migration in the PC3 prostate cancer cell line after 24 h
(compared to cells expressing vector alone). Migration was examined
in a Transwell migration assay (xCELLigence, Roche). Data repre-
sent the mean ± SEM of three experiments (n = 3 per treatment).
*P B 0.05, relative to control (empty vector)
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distinguishing proteolytic cleavage products of canonical
*3.3 kDa ghrelin from minighrelin, has so far yielded
mass spectrometry-based detection of minighrelin peptide
unsuccessful. Moreover, it is possible that the human exon
2-deleted preproghrelin variant is not cleaved after 13-AA
ghrelin peptide sequence and this would give rise to a
chimaeric minighrelin–obestatin peptide. Ghrelin and
obestatin are multifunctional peptide hormones [12, 50]
and chimaeric peptide hormones can have improved, or
novel, pharmacological properties compared to the indi-
vidual peptides alone [51, 52].
It is reasonable to assume that minighrelin is acylated
and functional regardless of its processed length. Human
exon 2-deleted preproghrelin and in1-ghrelin lack the
C-terminal 15 amino acids of the 28-amino acid canonical
ghrelin peptide, but are able to mimic the function of
ghrelin in vitro. Recent studies suggest that the C-terminal
region of ghrelin may be particularly important for stabil-
ising ghrelin in plasma [53, 54]. Therefore, in vivo, the
minighrelin peptide might have a shorter half-life than
canonical ghrelin and alternative splicing could provide a
mechanism for regulating the bioavailability of circulating
ghrelin. Nevertheless, even if short ghrelin peptides are less
stable in the circulation, ghrelin produced in the stomach
binds to its cognate receptor, GHSR1a, on vagal afferent
neurons to signal centrally [55, 56] and ghrelin has local
(autocrine and paracrine) effects in a number of cell types
[13]. Moreover, minighrelin retains the active core of
ghrelin [32–34] and it is now firmly established that short
synthetic ghrelin peptides have agonist activity [32, 53, 54,
57, 58], albeit with reduced potency compared to full-
length ghrelin. Interestingly, short functional ghrelin pep-
tides have been identified in the goldfish (Carassius
auratus) [5, 59]. We speculate that these short ghrelin
peptides in goldfish result from orthologous splice variants
of exon 2-deleted preproghrelin or in1-ghrelin. Further
proteomic and biochemical analyses are required to char-
acterise variants with minighrelin peptide sequences.
More broadly, it is critical to appreciate the transcrip-
tional complexity of the ghrelin gene locus in normal
physiology and disease. Emerging technologies, such as
RNA CaptureSeq which allows the detection of low-
abundance gene expression in selected loci [60], are likely
to greatly advance our understanding of the complex
ghrelin gene locus. Since the discovery of ghrelin [1],
approximately 8000 articles on ghrelin have been pub-
lished, with many articles referring to the measurement of
serum ghrelin levels and their association with physiology
or disease. Discrepancies between studies [4] may be
explained partly by the fact that most assays cannot cur-
rently discriminate between distinct ghrelin gene-derived
peptides. In particular, several studies have relied on
sandwich (two-site) ELISAs, with capture antibodies raised
against the C-terminal region of the 28-amino acid ghrelin
peptide [61, 62]. As these assays cannot detect minighrelin
peptides, this would lead to an underestimation of total
ghrelin levels. It may be necessary to conduct additional
studies under many different physiological and patho-
physiological conditions to ensure that the contribution of
ghrelin peptides is reliably assessed.
In summary, we provide preliminary evidence that ghrelin
gene-derived splice variants encoding C-terminally truncated
peptides that retain the active core (the first five amino acids)
of ghrelin, termed minighrelins, are conserved in vertebrates.
Minighrelin peptide is able to stimulate appetite in mice, and
preproghrelin splice variants that encode minighrelin are able
to mimic the actions of canonical ghrelin in vitro. These
findings add complexity to the study of ghrelin and further
impetus for the study of alternative splicing of the ghrelin gene
and the function of novel transcripts in diverse species.
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